<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03444376</url>
  </required_header>
  <id_info>
    <org_study_id>GX-188E-005</org_study_id>
    <nct_id>NCT03444376</nct_id>
  </id_info>
  <brief_title>The Combination of GX-188E Vaccination and Pembrolizumab in Patients With HPV 16 and/or 18+ Advanced Cervical Cancer</brief_title>
  <official_title>A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and Pembrolizumab in Patients With Advanced, Non-Resectable HPV Type 16 and/or 18 Positive Cervical Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Genexine, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Genexine, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Multi-Center, Open-label Phase Ib-II Trial of the Combination of GX-188E Vaccination and&#xD;
      Pembrolizumab in Patients with Advanced, Non-Resectable HPV-Positive Cervical Cancer&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label Phase Ib-II trial to evaluate the safety and efficacy of GX-188E (IM&#xD;
      administration using Ichor TDS-IM device) + pembrolizumab (P) in patients with advanced&#xD;
      HPV-16+ or HPV-18+ cervical cancer.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 23, 2018</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2021</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>DLT evaluation for safety and tolerability(part A)</measure>
    <time_frame>within 21days</time_frame>
    <description>Patient will be evaluated for the first 21 days for dose-limiting toxicities.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>ORR for efficacy(part B&amp;C)</measure>
    <time_frame>within 24 weeks</time_frame>
    <description>ORR within 24 weeks (ORR24) evaluated by RECIST v1.1</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ORR for efficacy(part A)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Overall Response Rate within 24 weeks (ORR24) by RECIST v1.1 and immune-related Response Criteria (irRC)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>BORR (part B&amp;C)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Best Overall Response Rate(BORR24) by RECIST v1.1</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time-to-Best Response</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Time-to-Best Response by RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response (DOR)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Duration of Response (DOR) by RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-Free Survival (PFS)</measure>
    <time_frame>up to 6 months</time_frame>
    <description>6month- PFS by RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS)</measure>
    <time_frame>up to 1 year</time_frame>
    <description>Overall Survival (OS) by RECIST v1.1 and iRECIST</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">60</enrollment>
  <condition>Cervical Cancer</condition>
  <arm_group>
    <arm_group_label>GX-188E, Keytruda</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>GX-188E: 1st day of week 1,2,4,7,13,19, 46/ 2mg Keytruda:Day 1 q3 weeks/ 200mg</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>GX-188E</intervention_name>
    <description>GX-188E (1.0mg/0.5ml/vial), Intramuscular administration using electroporator, Ichor TDS-IM device</description>
    <arm_group_label>GX-188E, Keytruda</arm_group_label>
    <other_name>Ichor Tri-Grid Delivery System</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Keytruda</intervention_name>
    <description>pembrolizumab(100mg/4mL/vial), Intravenous administration</description>
    <arm_group_label>GX-188E, Keytruda</arm_group_label>
    <other_name>Pembrolizumab</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Patients must be female and age â‰¥ 18 years (19 years for Korean sites)&#xD;
&#xD;
          2. Patients with histologically confirmed advanced or metastatic HPV-positive (HPV-16 or&#xD;
             HPV-18) cervical cancer, who have disease progression after treatment with all&#xD;
             available therapies for metastatic disease that are known to confer clinical benefit,&#xD;
             or are intolerant to treatment, or refuse standard treatment.&#xD;
&#xD;
          3. Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1&#xD;
&#xD;
          4. Life Expectancy of at least 6 months&#xD;
&#xD;
          5. Patients must agree to provide either an archival tumor tissue sample or fresh biopsy&#xD;
             sample for baseline biomarker tissue analyses, including staining for PD-L1. If&#xD;
             archival tissue is not available and the patient does not have biopsy-accessible tumor&#xD;
             lesions, the patient will be excluded.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Patient has disease that is suitable for local therapy administered with curative&#xD;
             intent.&#xD;
&#xD;
          2. Patient has a known additional malignancy that is progressing or has required active&#xD;
             treatment within the past 3 years.&#xD;
&#xD;
          3. Patient is expected to require any other form of antineoplastic therapy while on&#xD;
             study; including systemic chemotherapy, radiation therapy (except for palliative&#xD;
             purposes) biological therapy, or immunotherapy not specified in this protocol.&#xD;
&#xD;
          4. Patient has a history of active central nervous system (CNS) metastases and/or&#xD;
             carcinomatous meningitis.&#xD;
&#xD;
          5. Patients have received prior therapy with an anti-PD-1, anti-PD-L1, or anti PD-L2&#xD;
             agent or with an agent directed to another stimulatory or co-inhibitory T-cell&#xD;
             receptor (e.g., CTLA-4, OX 40, CD137) and was discontinued from that treatment due to&#xD;
             a Grade 3 or higher immune-related Adverse Event (irAE)&#xD;
&#xD;
          6. Patients with active autoimmune disease requiring systemic immunosuppressive treatment&#xD;
             within the past 2 years (i.e. with use of disease modifying agents, corticosteroids or&#xD;
             immunosuppressive drugs). Replacement therapy (eg, thyroxine, insulin, or physiologic&#xD;
             corticosteroid replacement therapy for adrenal or pituitary insufficiency, etc.) is&#xD;
             not considered a form of systemic treatment and is allowed.&#xD;
&#xD;
          7. Patients has had an allogeneic solid organ or allogeneic bone marrow transplant&#xD;
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Soo-Young Hur, M.D</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Catholic University of Korea</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Yoonjeong Choi</last_name>
    <phone>+82-31-628-3233</phone>
    <email>yoonjeong.choi@genexine.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <zip>42601</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>U-Eun Choi</last_name>
      <phone>+82-53-258-6678</phone>
      <email>ueun_@naver.com</email>
    </contact>
    <investigator>
      <last_name>Chi Heum Cho, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>National Cancer Center</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>10408</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ae jeong Choi</last_name>
      <phone>+82-31-920-0852</phone>
      <email>75334@ncc.re.kr</email>
    </contact>
    <investigator>
      <last_name>Myong Cheol Lim, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang Hospital</name>
      <address>
        <city>Gyeonggi-do</city>
        <zip>13620</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>HyunHee Lee</last_name>
      <phone>+82-31-787-8306</phone>
      <email>leehhni@gmail.com</email>
    </contact>
    <investigator>
      <last_name>Jae Hong No, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Severance Hospital, Yonsei University Health System</name>
      <address>
        <city>Seoul</city>
        <zip>03722</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SuYeon Kim</last_name>
      <phone>+82-2-2228-0570</phone>
      <email>SUE63@yuhs.ac</email>
    </contact>
    <investigator>
      <last_name>Sunghoon Kim, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>05505</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>In-Jung Nam</last_name>
      <phone>+82-2-3010-8697</phone>
      <email>nij82@amc.seoul.kr</email>
    </contact>
    <investigator>
      <last_name>Yong-Man Kim, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <zip>06351</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>MyungHee Nam</last_name>
      <email>myunghee.nam@samsung.com</email>
    </contact>
    <investigator>
      <last_name>Byoung-Gie Kim, M.D</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>06591</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ji Sun Roh, CRC</last_name>
      <phone>+82-2-2258-2738</phone>
      <email>jisun_8646@daum.net</email>
    </contact>
    <investigator>
      <last_name>Soo-Young Hur, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Korea University Guro Hospital</name>
      <address>
        <city>Seoul</city>
        <zip>152-703</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>SeungJi Yang, CRC</last_name>
      <phone>+82-2-2626-1637</phone>
      <email>gig10002@nate.com</email>
    </contact>
    <investigator>
      <last_name>Jae-Kwan Lee, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>January 25, 2018</study_first_submitted>
  <study_first_submitted_qc>February 19, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 23, 2018</study_first_posted>
  <last_update_submitted>July 31, 2020</last_update_submitted>
  <last_update_submitted_qc>July 31, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 4, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>keytruda</keyword>
  <keyword>pembrolizumab</keyword>
  <keyword>GX-188E</keyword>
  <keyword>TDS-IM device</keyword>
  <keyword>KEYNOTE-567</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

